Detalhe da pesquisa
1.
The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.
BMC Med
; 19(1): 60, 2021 02 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33632218
2.
Correction to: The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.
BMC Med
; 20(1): 99, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35227254
3.
Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data.
Lancet
; 383(9934): 2057-2064, 2014 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24650955
4.
Tuberculosis control in China: use of modelling to develop targets and policies.
Bull World Health Organ
; 93(11): 790-8, 2015 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26549907
5.
[A study on the cooperation between centers for disease control and special tuberculosis hospitals for treatment and management of multi-drug resistant tuberculosis].
Zhonghua Jie He He Hu Xi Za Zhi
; 37(10): 753-7, 2014 Oct.
Artigo
em Zh
| MEDLINE | ID: mdl-25537411
6.
The Impact of COVID-19 Epidemic on Tuberculosis Reports Among Students - Guizhou Province, China, 2020.
China CDC Wkly
; 4(11): 216-219, 2022 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35433075
7.
Development and Application of a Multidrug-Resistant Tuberculosis Case Management System - Yunnan Province, China, 2017-2020.
China CDC Wkly
; 4(38): 855-861, 2022 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36284689
8.
Characteristics of rifampicin-resistant tuberculosis detection in China, 2015-2019.
Infect Dis Poverty
; 10(1): 99, 2021 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34274020
9.
Epidemiological Characteristics of Rifampicin-Resistant Tuberculosis in Students - China, 2015-2019.
China CDC Wkly
; 3(26): 549-552, 2021 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34594933
10.
Practical Experiences of Delivering Multidrug-Resistant Tuberculosis Comprehensive Supportive Care Services in China.
China CDC Wkly
; 3(26): 566-568, 2021 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34594937
11.
Impact of the gate-keeping policies of China's primary healthcare model on the future burden of tuberculosis in China: a protocol for a mathematical modelling study.
BMJ Open
; 11(8): e048449, 2021 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34433597
12.
Is knowledge retained by healthcare providers after training? A pragmatic evaluation of drug-resistant tuberculosis management in China.
BMJ Open
; 9(3): e024196, 2019 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30904847
13.
Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors.
PLoS One
; 14(4): e0214943, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30958841
14.
Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China.
J Infect
; 76(4): 348-353, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29374587
15.
[Analysis of the cost of public health service items in four centers for disease control and prevention in county level in China].
Zhonghua Yu Fang Yi Xue Za Zhi
; 41(4): 262-5, 2007 Jul.
Artigo
em Zh
| MEDLINE | ID: mdl-17959044
16.
Comparing yield and relative costs of WHO TB screening algorithms in selected risk groups among people aged 65 years and over in China, 2013.
PLoS One
; 12(6): e0176581, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28594824
17.
The Global Fund in China: Multidrug-resistant tuberculosis nationwide programmatic scale-up and challenges to transition to full country ownership.
PLoS One
; 12(6): e0177536, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28628669
18.
Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: a before-and-after study.
Lancet Glob Health
; 3(4): e217-28, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25794675